Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mugsy At 900

<< Previous

Bullboard Posts

Next >>

Comment by Yellowknifer69on Mar 31, 2021 3:25pm

204 Views

Post# 32916105

RE:RE:RE:Mugsy At 900

Hello and good afternoon Longs:

Not much going on here these days but thougt I would weigh in on the thread.

Just imagine if you added in the thumbs up from when Mugsy was DrippingSnot?! The guy would probably be up to 910 likes. Lol

On all things Antibe, by my count we are probably due a decent NR in the next week or two.

Come on Dan let's get it rolling!

Yellowknifer

<< Previous

Bullboard Posts

Next >>

Viva Gold brings new drill program and updated PEA to Nevada project